FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313880107> ?p ?o ?g. }

• W4313880107 abstract "Primary angle-closure glaucoma is a type of glaucoma associated with a physically obstructed anterior chamber angle. For example, contact between the iris and lens at the pupillary margin creates a pupillary block that increases resistance to aqueous outflow. Obstruction of the anterior chamber angle blocks drainage of fluids (aqueous humor) within the eye and may raise intraocular pressure (IOP). Elevated IOP is associated with glaucomatous optic nerve damage and visual field loss. Laser peripheral iridotomy ('iridotomy') is a procedure to eliminate pupillary block by allowing aqueous humor to pass directly from the posterior to anterior chamber, which is achieved by creating a hole in the iris using laser. Iridotomy is used to treat patients with primary angle-closure glaucoma, patients with primary angle-closure (narrow angles and no signs of glaucomatous optic neuropathy), and patients who are primary angle-closure suspects (patients with reversible obstruction). However, the effectiveness of iridotomy on slowing progression of visual field loss is uncertain.To assess the effects of iridotomy compared with no iridotomy for primary angle-closure glaucoma, primary angle-closure, and primary angle-closure suspect.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10), which contains the Cochrane Eyes and Vision Trials Register; MEDLINE Ovid; Embase Ovid; PubMed; LILACS; ClinicalTrials.gov; and the WHO ICTRP. The date of the most recent search was 10 October 2021.Randomized or quasi-randomized controlled trials that compared iridotomy with no iridotomy in primary angle-closure suspects, people with primary angle-closure, or people with primary angle-closure glaucoma in one or both eyes were eligible.We used standard Cochrane methodology and assessed the certainty of the body of evidence for prespecified outcomes using the GRADE approach.We identified four studies (3086 eyes of 1543 participants) that compared iridotomy with no iridotomy in participants (range of mean age 59.6 to 62.9 years) who were primary angle-closure suspects from China, Singapore, or the UK. Study investigators randomized one eye of each participant to iridotomy and the other to no iridotomy. Two studies provided long-term (five or more years) results. We judged the certainty of the evidence as moderate to low across the prespecified outcomes, downgrading for high risk of bias (e.g. performance and detection biases) and imprecision of results. Meta-analyses of data from two studies suggest that iridotomy probably results in little to no difference in IOP compared with no iridotomy at one year (mean difference (MD) 0.04 mm Hg, 95% confidence interval (CI) -0.17 to 0.24; I2 = 65%; 2598 eyes of 1299 participants; moderate certainty evidence) and five years (MD 0.12 mm Hg, 95% CI -0.11 to 0.35; I2 = 0%; 2016 eyes of 1008 participants), and in best-corrected visual acuity measured as logMAR at one year (MD 0.00, 95% CI -0.01 to 0.01; I2 = 69%; 2596 eyes of 1298 participants; moderate certainty evidence) and five years (MD 0.01, 95% CI -0.01 to 0.03; I2 = 0%; 2002 eyes of 1001 participants). In terms of gonioscopic findings, eyes treated with iridotomy likely had wider angles in Shaffer grading scale (MD 4.93 units, 95% CI 4.73 to 5.12; I2 = 59%; 2598 eyes of 1299 participants at one year; MD 5.07, 95% CI 4.78 to 5.36; I2 = 97%; 2016 eyes of 1008 participants at five years; moderate certainty evidence) and experienced fewer peripheral anterior synechiae (PAS) than eyes that received no iridotomy at five years (risk ratio (RR) 0.41, 95% CI 0.24 to 0.67; I2 = 28%; 2 studies, 2738 eyes of 1369 participants), but the evidence was less conclusive at one year (RR 0.62, 95% CI 0.25 to 1.54; I2 = 57%; 3 studies, 2896 eyes of 1448 participants; low certainty evidence). No studies reported data on the proportion of participants with progressive visual field loss during follow-up (the primary outcome of this review), mean number of medications to control IOP, or quality of life outcomes. Low certainty evidence suggests that iridotomy may result in little to no difference in the incidence of acute angle-closure (RR 0.29, 95% CI 0.07 to 1.20; I2 = 0%; 3 studies, 3006 eyes of 1503 participants). Other ocular adverse events (e.g. eye pain, dry eye, redness of eyes, and ocular discomfort), although rare, were more common in eyes treated with iridotomy than in eyes in the control group. AUTHORS' CONCLUSIONS: We did not find sufficient evidence to draw any meaningful conclusions on the use of iridotomy for the purpose of slowing progression of visual field loss. No study reported on progressive visual field loss, the primary outcome of this review. Although there is moderate certainty evidence that iridotomy results in improved gonioscopic findings, in is unclear if these findings translate to clinically meaningful benefits." @default.
• W4313880107 created "2023-01-10" @default.
• W4313880107 creator A5011126528 @default.
• W4313880107 creator A5029844605 @default.
• W4313880107 creator A5043086065 @default.
• W4313880107 date "2023-01-09" @default.
• W4313880107 modified "2023-09-25" @default.
• W4313880107 title "Iridotomy to slow progression of visual field loss in angle-closure glaucoma" @default.
• W4313880107 cites W116053659 @default.
• W4313880107 cites W1541202600 @default.
• W4313880107 cites W1558633346 @default.
• W4313880107 cites W1581790161 @default.
• W4313880107 cites W1599160970 @default.
• W4313880107 cites W1667265675 @default.
• W4313880107 cites W1885333333 @default.
• W4313880107 cites W1945693830 @default.
• W4313880107 cites W1947101754 @default.
• W4313880107 cites W1982243649 @default.
• W4313880107 cites W2004716771 @default.
• W4313880107 cites W2014701189 @default.
• W4313880107 cites W2016476208 @default.
• W4313880107 cites W2017145365 @default.
• W4313880107 cites W2018553846 @default.
• W4313880107 cites W2024563129 @default.
• W4313880107 cites W2036209772 @default.
• W4313880107 cites W2038730003 @default.
• W4313880107 cites W2045488918 @default.
• W4313880107 cites W2057266151 @default.
• W4313880107 cites W2061508739 @default.
• W4313880107 cites W2063050873 @default.
• W4313880107 cites W2063969726 @default.
• W4313880107 cites W2069632685 @default.
• W4313880107 cites W2077421021 @default.
• W4313880107 cites W2079069831 @default.
• W4313880107 cites W2083654146 @default.
• W4313880107 cites W2091039953 @default.
• W4313880107 cites W2093188586 @default.
• W4313880107 cites W2099260394 @default.
• W4313880107 cites W2110413534 @default.
• W4313880107 cites W2112948350 @default.
• W4313880107 cites W2125242498 @default.
• W4313880107 cites W2125435699 @default.
• W4313880107 cites W2134954483 @default.
• W4313880107 cites W2137212392 @default.
• W4313880107 cites W2143139917 @default.
• W4313880107 cites W2160605010 @default.
• W4313880107 cites W2165504752 @default.
• W4313880107 cites W2167851590 @default.
• W4313880107 cites W2169113983 @default.
• W4313880107 cites W2169961704 @default.
• W4313880107 cites W2314055324 @default.
• W4313880107 cites W2403974534 @default.
• W4313880107 cites W2410087972 @default.
• W4313880107 cites W2417508626 @default.
• W4313880107 cites W2417858857 @default.
• W4313880107 cites W2418264459 @default.
• W4313880107 cites W2442542656 @default.
• W4313880107 cites W2463291196 @default.
• W4313880107 cites W2466611524 @default.
• W4313880107 cites W2525441444 @default.
• W4313880107 cites W2750726460 @default.
• W4313880107 cites W2753108291 @default.
• W4313880107 cites W2801691481 @default.
• W4313880107 cites W2804523267 @default.
• W4313880107 cites W2807546558 @default.
• W4313880107 cites W2808450522 @default.
• W4313880107 cites W2896741076 @default.
• W4313880107 cites W2910671987 @default.
• W4313880107 cites W2917156239 @default.
• W4313880107 cites W2922216742 @default.
• W4313880107 cites W2965585302 @default.
• W4313880107 cites W2971703805 @default.
• W4313880107 cites W2973172640 @default.
• W4313880107 cites W2990546634 @default.
• W4313880107 cites W3001068555 @default.
• W4313880107 cites W3027635388 @default.
• W4313880107 cites W3123679721 @default.
• W4313880107 cites W3176817792 @default.
• W4313880107 cites W3185432292 @default.
• W4313880107 cites W3196301313 @default.
• W4313880107 cites W4210951267 @default.
• W4313880107 cites W4232058719 @default.
• W4313880107 cites W4290105886 @default.
• W4313880107 doi "https://doi.org/10.1002/14651858.cd012270.pub3" @default.
• W4313880107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36621864" @default.
• W4313880107 hasPublicationYear "2023" @default.
• W4313880107 type Work @default.
• W4313880107 citedByCount "1" @default.
• W4313880107 countsByYear W43138801072018 @default.
• W4313880107 crossrefType "journal-article" @default.
• W4313880107 hasAuthorship W4313880107A5011126528 @default.
• W4313880107 hasAuthorship W4313880107A5029844605 @default.
• W4313880107 hasAuthorship W4313880107A5043086065 @default.
• W4313880107 hasConcept C118487528 @default.
• W4313880107 hasConcept C119767625 @default.
• W4313880107 hasConcept C2776058522 @default.
• W4313880107 hasConcept C2776407710 @default.
• W4313880107 hasConcept C2778527774 @default.
• W4313880107 hasConcept C2780892088 @default.
• W4313880107 hasConcept C2781092963 @default.

• next